NO20015003L - Nukleinsyrer kodende for CD40/CD40L kimeriske polypeptider, fremgangsmåter for fremstilling og anvendelse derav - Google Patents

Nukleinsyrer kodende for CD40/CD40L kimeriske polypeptider, fremgangsmåter for fremstilling og anvendelse derav

Info

Publication number
NO20015003L
NO20015003L NO20015003A NO20015003A NO20015003L NO 20015003 L NO20015003 L NO 20015003L NO 20015003 A NO20015003 A NO 20015003A NO 20015003 A NO20015003 A NO 20015003A NO 20015003 L NO20015003 L NO 20015003L
Authority
NO
Norway
Prior art keywords
preparation
methods
nucleic acids
acids encoding
chimeric polypeptides
Prior art date
Application number
NO20015003A
Other languages
English (en)
Norwegian (no)
Other versions
NO20015003D0 (no
Inventor
Frank Dicker
Thomas Friess
Gerd Maass
Ulrich Pessara
Werner Scheuer
Stefan Seeber
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP99107611A external-priority patent/EP1067194A1/fr
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20015003L publication Critical patent/NO20015003L/no
Publication of NO20015003D0 publication Critical patent/NO20015003D0/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
NO20015003A 1999-04-16 2001-10-15 Nukleinsyrer kodende for CD40/CD40L kimeriske polypeptider, fremgangsmåter for fremstilling og anvendelse derav NO20015003D0 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP99107611A EP1067194A1 (fr) 1999-04-16 1999-04-16 Vecteurs contenant des gènes codant pour CD40 et/ou CD40L, sous le contrôle du promoteur inductibles à cytokine, qui est un promoteur d'amyloide sérique à phase aigue humaine. Procédés de leur fabrication et leurs utilisations
EP99113967 1999-07-17
PCT/EP2000/003318 WO2000063395A1 (fr) 1999-04-16 2000-04-13 Acides nucleiques codant pour des polypeptides chimeres cd40/cd40l, leurs procedes de production et leurs utilisations

Publications (2)

Publication Number Publication Date
NO20015003L true NO20015003L (no) 2001-10-15
NO20015003D0 NO20015003D0 (no) 2001-10-15

Family

ID=26152970

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20015003A NO20015003D0 (no) 1999-04-16 2001-10-15 Nukleinsyrer kodende for CD40/CD40L kimeriske polypeptider, fremgangsmåter for fremstilling og anvendelse derav

Country Status (8)

Country Link
EP (1) EP1173589A1 (fr)
JP (1) JP2003508016A (fr)
AR (1) AR023482A1 (fr)
AU (1) AU3966200A (fr)
CA (1) CA2369820A1 (fr)
IL (1) IL144952A0 (fr)
NO (1) NO20015003D0 (fr)
WO (1) WO2000063395A1 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002028905A2 (fr) 2000-10-02 2002-04-11 Chiron Corporation Anticorps humains anti-cd40
WO2002036769A2 (fr) * 2000-10-31 2002-05-10 F. Hoffmann-La Roche Ag Acides nucleiques codant des polypeptides chimeriques cd40/cd40l, procedes de production et utilisations de ces acides nucleiques
EP1844815B1 (fr) 2003-11-04 2011-09-14 Novartis Vaccines and Diagnostics, Inc. Combination d'anticorps anti-CD20 et d'anticorps anti-CD40 pour le traitment des cancers liés aux lymphocytes B
ATE447412T1 (de) 2003-11-04 2009-11-15 Novartis Vaccines & Diagnostic Antagonist-anti-cd40-monoklonale antikörper und anwendungsverfahren
EP1680141B8 (fr) 2003-11-04 2011-01-12 Novartis Vaccines and Diagnostics, Inc. Procedes therapeutiques de tumeurs solides exprimant l'antigene de surface cellulaire cd40
JP4765037B2 (ja) 2003-11-04 2011-09-07 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 慢性リンパ球性白血病の処置のためのアンタゴニスト抗ｃｄ４０モノクローナル抗体の使用
US20070218060A1 (en) 2003-11-04 2007-09-20 Chiron Corporation Use of Antagonist Anti-Cd40 Monoclonal Antibodies for Treatment of Multiple Myeloma
EP2312315A1 (fr) 2005-05-18 2011-04-20 Novartis AG Procédés pour le diagnostic et le traitement des maladies ayant une composante auto-immune et/ou inflammatoire
NZ571757A (en) 2006-04-21 2012-01-12 Novartis Ag Antagonist anti-CD40 antibody pharmaceutical compositions comprising arginine-HCl and a citrate or citric acid buffer
EP2066339B1 (fr) 2006-09-18 2014-08-13 The Board Of Trustees Of The University Of Arkansas Compositions et procédés pour améliorer des réponses immunes
US9125854B2 (en) 2007-10-30 2015-09-08 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to flagellated bacterium
EP3097926B1 (fr) 2007-11-01 2019-10-02 The Board of Trustees of the University of Arkansas Compositions et procédés pour amplifier des réponses immunitaires à l'eimeria
JP5568807B2 (ja) * 2008-06-06 2014-08-13 静岡県 プロテオミクス解析を用いたメラノーママーカーの同定
JP6242050B2 (ja) 2010-01-21 2017-12-06 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー 免疫応答を増強するワクチンベクターおよび方法
KR101881611B1 (ko) 2010-06-09 2018-07-25 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 캄필로박터 감염을 감소시키기 위한 백신 및 방법
WO2012075111A1 (fr) 2010-11-30 2012-06-07 Novartis Ag Utilisation d'anticorps anti-cd40 en thérapie combinée contre des cancers associés aux cellules b
ES2968398T3 (es) 2013-02-14 2024-05-09 Univ Arkansas Composiciones y métodos para potenciar las respuestas inmunitarias a Eimeria o limitar la infección por Eimeria
EP3578190A1 (fr) 2013-03-15 2019-12-11 The Board of Trustees of the University of Arkansas Compositions et procédés pour améliorer les réactions immunitaires aux pathogènes entériques
AR108688A1 (es) 2016-05-03 2018-09-19 Univ Arkansas Vector de vacuna de levadura que incluye polipéptidos inmunoestimuladores y antigénicos, métodos para su uso
CA3044424C (fr) * 2016-11-21 2023-05-23 Nant Holdings Ip, Llc Traitement combine fractal
US20200024326A1 (en) * 2018-06-14 2020-01-23 Nantbio, Inc. Tnf-type receptor-ligand fusion proteins and methods
WO2020073045A1 (fr) * 2018-10-05 2020-04-09 Nantcell, Inc. Combo cd40 et cd40l dans un véhicule de vaccin à adénovirus

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2198025T3 (es) * 1991-10-25 2004-01-16 Immunex Corporation Anticuerpos contra cd40-l.
US5716805A (en) * 1991-10-25 1998-02-10 Immunex Corporation Methods of preparing soluble, oligomeric proteins
US7070771B1 (en) * 1996-12-09 2006-07-04 Regents Of The University Of California Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells

Also Published As

Publication number Publication date
IL144952A0 (en) 2002-06-30
EP1173589A1 (fr) 2002-01-23
JP2003508016A (ja) 2003-03-04
WO2000063395A1 (fr) 2000-10-26
CA2369820A1 (fr) 2000-10-26
AU3966200A (en) 2000-11-02
NO20015003D0 (no) 2001-10-15
AR023482A1 (es) 2002-09-04

Similar Documents

Publication Publication Date Title
NO20015003D0 (no) Nukleinsyrer kodende for CD40/CD40L kimeriske polypeptider, fremgangsmåter for fremstilling og anvendelse derav
ZA200110161B (en) Anti-avB3 recombinant human antibodies, nucleic acids encoding same and methods of use.
WO2003023008A8 (fr) Polypeptides therapeutiques, acides nucleiques les codant, et modalites d'emploi correspondantes
NO20024774L (no) [1,4`]-bipiperidinforbindelsr, fremgangsmate til fremstilling derav og anvendelse dera, farmasoytisk preparat, samt mellomprodukter
AU2002221780A1 (en) Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
EP1576169A4 (fr) Polypeptides therapeutiques, acides nucleiques codant pour ceux-ci et methodes d'utilisation associees
AU9633301A (en) Paad domain-containing polypeptides, encoding nucleic acids, and methods of use
EP1576108A4 (fr) Nitrilases, acides nucleiques les codant et leurs procedes de production et d'utilisation
EP1487864A4 (fr) Polypeptides therapeutiques, acides nucleiques codant ces polypeptides et methodes d'utilisation associees
AU2002356534A8 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
EP1446419A4 (fr) Polypeptides therapeutiques, acides nucleiques codant ceux-ci et procedes d'utilisation
EP1401858A4 (fr) Polypeptides therapeutiques, acides nucleiques codant ces polypeptides et procedes d'utilisation
EP1432726A4 (fr) Polypeptides therapeutiques, acides nucleiques codant ces derniers et methodes d'utilisation correspondantes
AU2003217956A8 (en) Therapeutic polypeptides, nucleic acids encoding same and methods of use
EP1695078A4 (fr) Polypeptides de metadherine codant des acides nucleiques et procedes d'utilisation
AU2003247537A8 (en) Chd5 encoding nucleic acids, polypeptides, antibodies and methods of use thereof
EP1539985A4 (fr) Polypeptides therapeutiques, acides nucleiques encodant ces polypeptides, et procedes d'utilisation
EP1532238A4 (fr) Polypeptides therapeutiques, acides nucleiques les codant et procedes d'utilisation correspondant
AU2002365905A8 (en) Transaminases, nucleic acids encoding them and methods of making and using them
EP1443913A4 (fr) Polypeptides therapeutiques, acides nucleiques encodant ces polypeptides et leurs procedes d'utilisation
EP1399537A4 (fr) Polypeptides therapeutiques, acides nucleiques les codant, et procedes d'utilisation
EP1549671A4 (fr) Polypeptides therapeutiques, acides nucleiques codant ces polypeptides et methodes d'utilisation associees
AU2002365216A8 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
AU2003304034A8 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2003060149A9 (fr) Polypeptides therapeutiques, acides nucleiques codant ces polypeptides et procedes d'utilisation

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application